STING1 and melanoma: Accordingly, Zheng et al. reported ADU-S100, a CDN STING agonist, formulated with chimeric polymers to significantly improve tumor retention and cytosolic delivery, promoting the activation of the pathway STING and the antitumor immunotherapy of malignant melanoma in mice [136].